Intriguingly, this therapy not only reversed the local antitumor immune responses in tumor sites but also restored systemic antitumor immunity as shown by the increased frequency and activation of splenic CD8+ T cells and NK cells accompanied with reduced Treg cells (Figure S3). Here, CD8A is linked to neoplasm.